CHDI joins Alnylam, Medtronic in HD partnership

Not-for-profit CHDI Foundation Inc. agreed to initially fund up to 50% of IND-enabling activities for ALN-HTT, a preclinical Huntington's disease (HD) candidate from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Medtronic Inc. (NYSE:MDT). The foundation said the amount of funding would be in excess of $10 million. ALN-HTT is an siRNA against the huntingtin gene delivered to the CNS via Medtronic's implantable pump infusion system. ...